Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Marco Basset, MD, Christoph Kimmich, Tobias Dittrich, MD, Kaya Veelken, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Anja Seckinger, MD, Anna Jauch, Carsten Mueller-Tidow, MD, Ute Hegenbart, MD, Stefan Schönland, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142701

Published: 2020

Journal Articles

Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs

Laurie Herviou, Alboukadel Kassambara, PhD, Stephanie Boireau, PhD, Nicolas Robert, Guilhem Requirand, Laure Vincent, MD, Anja Seckinger, MD, Hartmut Goldschmidt, MD, Dirk Hose, MD, Giacomo Cavalli, PhD, Jerome Moreaux, PhD

Blood (2016) 128 (22): 311.

https://doi.org/10.1182/blood.V128.22.311.311

Published: 2016

Journal Articles

Asymptomatic Multiple Myeloma - Background of Progression, Evolution, and Prognosis

Blood (2016) 128 (22): 235.

https://doi.org/10.1182/blood.V128.22.235.235

Published: 2016

Journal Articles

On the Redox Profile of B- Cell Terminal Differentiation and Multiple Myeloma: New Insights and Therapeutic Opportunities

Wafa Hassen, PhD, Alboukadel Kassambara, PhD, Michel Jourdan, Stephanie Boireau, PhD, Anja Seckinger, MD, Dirk Hose, Yubin Kang, MD, Bernard Klein, Jerome Moreaux, PhD

Blood (2016) 128 (22): 5644.

https://doi.org/10.1182/blood.V128.22.5644.5644

Published: 2016

Journal Articles

Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma

Maximilian Merz, MD, Thomas Hielscher, Anja Seckinger, MD, Dirk Hose, MD, Uta Bertsch, MD, Kai Neben, MD, Marc S Raab, MD, Igor Blau, Hans Walter Lindemann, MD, Ingo GH Schmidt-Wolf, MD, Christof Scheid, MD PhD, Mathias Haenel, MD, Katja Weisel, MD, Hartmut Goldschmidt, MD, Anna Jauch, PhD, Jens Hillengass, MD

Blood (2016) 128 (22): 4415.

https://doi.org/10.1182/blood.V128.22.4415.4415

Published: 2016

Journal Articles

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

Sandra Sauer, MD, Jens Hillengass, MD, Barbara Wagner, Daniel Spira, MD, Marc Andre Weber, MD, Stefan Hemmer, Stefan Delorme, MD, Jennifer Mosebach, MD, Martin Freitag, MD, Antonia Strauss-Dimitrakopoulou, Hartmut Goldschmidt, MD, Mindaugas Andrulis, MD, Brian Durie, MD, Dirk Hose, MD, Anja Seckinger, MD

Blood (2016) 128 (22): 4419.

https://doi.org/10.1182/blood.V128.22.4419.4419

Published: 2016

Journal Articles

A Small Molecule That Selectively Targets BLM Helicase Has a Therapeutic Interest in Multiple Myeloma

Elena Viziteu, Yea Lih Lin, Laure Vincent, MD, Anja Seckinger, MD, Dirk Hose, Angelos Constantinou, Bernard Klein, Philippe Pasero, PhD, Jerome Moreaux, PhD

Blood (2016) 128 (22): 4433.

https://doi.org/10.1182/blood.V128.22.4433.4433

Published: 2016

Journal Articles

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

Stefano Malvestiti, Fengjuan Fan, PhD, Muhammad Hasan Bashari, MD, Eugenio Morelli, MD, Sonia Vallet, MD, Martin Sattler, PhD, Latifa Bakiri, PhD, Anja Seckinger, MD, Dirk Hose, MD, Hartmut Goldschmidt, MD, Inka Zörnig, PhD, Martin Pecherstorfer, MD, Erwin Wagner, PhD, Pierfrancesco Tassone, MD, Dirk Jäger, MD, Klaus Podar, MD MSc PhD

Blood (2016) 128 (22): 2091.

https://doi.org/10.1182/blood.V128.22.2091.2091

Published: 2016

Journal Articles

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

Tobias Meissner, Anja Seckinger, MD, Kari Hemminki, PhD, Uta Bertsch, MD, Asta Foersti, Mathias Haenel, MD, Jan Duering, Hans-Juergen Salwender, MD, Hartmut Goldschmidt, MD, Gareth J Morgan, MDPhD, Dirk Hose, MD, Niels Weinhold, PhD

Blood (2015) 126 (23): 2996.

https://doi.org/10.1182/blood.V126.23.2996.2996

Published: 2015

Journal Articles

Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma

Julie Devin, Elena Viziteu, Laurie Herviou, Anja Seckinger, MD, Grandmougin Camille, Hartmut Goldschmidt, MD, Laure Vincent, MD, Philippe Pasero, PhD, Dirk Hose, MD, Bernard Klein, PhD, Jerome Moreaux, PhD

Blood (2015) 126 (23): 1771.

https://doi.org/10.1182/blood.V126.23.1771.1771

Published: 2015

Journal Articles

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

Anja Seckinger, MD, Jose Antonio Delgado, Laura Moreno, Brigitte Neuber, PhD, Anna Grab, PhD, Susanne Lipp, MS, Juana Merino, MDPhD, Minh Diem Vu, PhD, Klaus Strein, MD PhD, Felipe Prosper, MDPhD, Michael Hundemer, MD, Jesus San Miguel, MDPhD, Dirk Hose, MD, Bruno Paiva, PhD

Blood (2015) 126 (23): 117.

https://doi.org/10.1182/blood.V126.23.117.117

Published: 2015

Journal Articles

Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]

Blood (2014) 124 (21): 2071.

https://doi.org/10.1182/blood.V124.21.2071.2071

Published: 2014

Journal Articles

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

Ken Maes, Eva De Smedt, Kassambara Alboukadel, PhD, Dirk Hose, MD PhD, Anja Seckinger, MD PhD, Els Van Valckenborgh, PhD, Eline Menu, PhD, Bernard Klein, MD PhD, Karin Vanderkerken, PhD, Jerome Moreaux, PhD, Elke De Bruyne, PhD

Blood (2014) 124 (21): 3375.

https://doi.org/10.1182/blood.V124.21.3375.3375

Published: 2014

Journal Articles

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Anja Seckinger, MD, Tobias Meißner, PhD, Uta Bertsch, MD, Hans Salwender, MD, Jan Dürig, MD, Mathias Hänel, MD, Igor W. Blau, MD, Christof Scheid, MD, Katja Weisel, MD, Bernard Klein, PhD, Hartmut Goldschmidt, MD, Dirk Hose, Dr. med. dipl.-phys.

Blood (2013) 122 (21): 1863.

https://doi.org/10.1182/blood.V122.21.1863.1863

Published: 2013

Journal Articles

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

Blood (2013) 122 (21): 1897.

https://doi.org/10.1182/blood.V122.21.1897.1897

Published: 2013

Journal Articles

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Blood (2013) 122 (21): 3369.

https://doi.org/10.1182/blood.V122.21.3369.3369

Published: 2013

Journal Articles

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

Arnold Bolomsky, Dirk Hose, MD, Martin Schreder, MD, Anja Seckinger, MD, Tobias Meißner, Bernard Klein, Daniel Heintel, Sabine Pfeifer, Heinz Ludwig, Niklas Zojer

Blood (2012) 120 (21): 3947.

https://doi.org/10.1182/blood.V120.21.3947.3947

Published: 2012

Journal Articles

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

Mathias Witzens-Harig, MD, Dirk Hose, MD, PhD, Simone Jünger, Christina Pfirschke, Nisit Khandelwal, Anja Seckinger, MD, Heinke Conrad, Bettina Brackertz, Thierry Reme, Brigittte Gückel, Tobias Meissner, Michael Hundemer, Anthony D Ho, MD, Jean-Francois Rossi, MD, PhD, Kai Neben, MD, Helga Bernhard, MD, Hartmut Goldschmidt, MD, Bernard Klein, Philipp Beckhove

Blood (2012) 120 (21): 2942.

https://doi.org/10.1182/blood.V120.21.2942.2942

Published: 2012

Journal Articles

The Proportion of Clonal Plasma Cells In the Bone Marrow Analyzed by FISH Rather Than Single Chromosomal Abnormalities Predict Progression From Smoldering to Symptomatic Multiple Myeloma

Kai Neben, MD, Anna Jauch, Ph.D., Dirk Hose, MD, Christiane Heiss, Thomas Hielscher, Uta Bertsch, MD, Anja Seckinger, MD, Jens Hillengass, MD, Marc S. Raab, MD, Anthony D. Ho, MD, FRCPC, Hartmut Goldschmidt, MD

Blood (2010) 116 (21): 2950.

https://doi.org/10.1182/blood.V116.21.2950.2950

Published: 2010

Journal Articles

Mesenchymal Stromal Cells Derived from Human Non-Small Cell Lung Cancer, Normal Lung Tissue, and Bone Marrow: Differences in Frequency, Cytogenetics, Proliferation Behavior, and Chemosensitivity - Implications for Cancer Therapy.

Sandra Gottschling, MD, Michael Meister, PhD, Anna Jauch, PhD, Ulf C. Krause, MD, Anja Seckinger, MD, Hans Hoffmann, MD, Hendrik Dienemann, MD, Ho D. Anthony, MD PhD, Michael Thomas, MD

Blood (2007) 110 (11): 1925.

https://doi.org/10.1182/blood.V110.11.1925.1925

Published: 2007

NARROW

Gain 1q21 Is an Adverse Prognostic Factor in Patients with Relapsed/Refractory AL Amyloidosis Treated with Lenalidomide and Dexamethasone

Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs

Asymptomatic Multiple Myeloma - Background of Progression, Evolution, and Prognosis

On the Redox Profile of B- Cell Terminal Differentiation and Multiple Myeloma: New Insights and Therapeutic Opportunities

Longitudinal Fluorescence in Situ Hybridization at Primary Diagnosis and Relapse Reveals Clonal Evolution after Autologous Stem Cell Transplantation in Multiple Myeloma

Prospective Investigation of Genetic Alterations in Osteolytic Lesions Compared to Paired Random Aspirates

A Small Molecule That Selectively Targets BLM Helicase Has a Therapeutic Interest in Multiple Myeloma

The Pathophysiologic Role of JunB in Multiple Myeloma Pathogenesis: Focus on Bone Marrow Angiogenesis

Profound Impact of Sample Processing Delay on Gene Expression of Multiple Myeloma Plasma Cells

Inhibition of SUV39H Methyltransferase As a Potent Therapeutic Target in Multiple Myeloma

Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma

Prediction of Progression of Smouldering into Therapy Requiring Multiple Myeloma By Easily Accessible Clinical Factors [in 527 Patients]

The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma

Bone Turnover In Multiple Myeloma: Impact Of Bortezomib-Based Induction Therapy, High-Dose Melphalan, and Lenalidomide Consolidation On Osteoblast and Osteoclast Function Within The GMMG-MM5 Trial

Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial

GMMG MM5 Trial In Newly Diagnosed Multiple Myeloma To Evaluate PAd Vs VCD Induction Prior To High Dose Treatment Followed By Lenalidomide Consolidation and Maintenance – Final Analysis On Induction Therapy

Insulin Like Growth Factor Binding Protein 7 (IGFBP7) Is Downregulated in Multiple Myeloma with Consequneces for Myeloma Cell Growth and Bone Disease

Human Multiple Myeloma and Breast Cancer Cells Evade Immune Rejection Through Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6.

The Proportion of Clonal Plasma Cells In the Bone Marrow Analyzed by FISH Rather Than Single Chromosomal Abnormalities Predict Progression From Smoldering to Symptomatic Multiple Myeloma

Mesenchymal Stromal Cells Derived from Human Non-Small Cell Lung Cancer, Normal Lung Tissue, and Bone Marrow: Differences in Frequency, Cytogenetics, Proliferation Behavior, and Chemosensitivity - Implications for Cancer Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only